Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Conley

Showing results (31-40 of 281) with videos related to

Pageof 29
Sort By:
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
Dialogues in Clinical Neuroscience|October 29, 2011
Treatment of the special patient with schizophreniaR R Conley, D L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
The American Journal of Psychiatry|December 7, 2007
Challenge to atypical antipsychotic drug effect on cognitionWilliam T Carpenter, Robert R Conley
Nursing Management|November 10, 1998
A silent reportM L Barbera, R Conley, M Postell
The American Journal of Digestive Diseases|September 1, 1975
Duodenal-jejunal ulcers and recurrent hemorrhage: diagnostic value of total enteroscopyD R Conley, M Feffer, H Cove
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 2, 2000
On schizophrenia and new generation drugsW T Carpenter, R Conley, B Kirkpatrick
The American Journal of Psychiatry|August 2, 2001
Biperiden for excessive sweating from clozapineC Richardson, D L Kelly, R R Conley
Statistics in Medicine|October 30, 2004
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at riskRobert P McMahon, Stephan Arndt, Robert R Conley
Journal of Health Care Law & Policy|December 3, 2004
Assessment of capacity to give consent to research participation: state-of-the-art and beyondE G DeRenzo, R R Conley, R Love
Pageof 29

Showing results (31-40 of 281) with videos related to

Sort By:
Pageof 29
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
Dialogues in Clinical Neuroscience|October 29, 2011
Treatment of the special patient with schizophreniaR R Conley, D L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
The American Journal of Psychiatry|December 7, 2007
Challenge to atypical antipsychotic drug effect on cognitionWilliam T Carpenter, Robert R Conley
Nursing Management|November 10, 1998
A silent reportM L Barbera, R Conley, M Postell
The American Journal of Digestive Diseases|September 1, 1975
Duodenal-jejunal ulcers and recurrent hemorrhage: diagnostic value of total enteroscopyD R Conley, M Feffer, H Cove
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 2, 2000
On schizophrenia and new generation drugsW T Carpenter, R Conley, B Kirkpatrick
The American Journal of Psychiatry|August 2, 2001
Biperiden for excessive sweating from clozapineC Richardson, D L Kelly, R R Conley
Statistics in Medicine|October 30, 2004
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at riskRobert P McMahon, Stephan Arndt, Robert R Conley
Journal of Health Care Law & Policy|December 3, 2004
Assessment of capacity to give consent to research participation: state-of-the-art and beyondE G DeRenzo, R R Conley, R Love
Pageof 29